Phase I Dose-Escalation Study of Docetaxel, Cisplatin, and 5-Fluorouracil Combination Chemotherapy in Patients With Advanced Esophageal Carcinoma

A dose-escalation study of docetaxel (DOC), cisplatin (CDDP), and 5-fluorouracil (5-FU; DCF combination regimen) was performed to determine the maximum-tolerated dose (MTD), recommended dose (RD) and dose-limiting toxicities (DLT) in advanced esophageal carcinoma. Eighteen patients with esophageal c...

Full description

Saved in:
Bibliographic Details
Published in:International surgery 2015-06, Vol.100 (6), p.1153-1158
Main Authors: Satomura, Hitoshi, Nakajima, Masanobu, Sasaki, Kinro, Yamaguchi, Satoru, Domeki, Yasushi, Takahashi, Masakazu, Muroi, Hiroto, Kubo, Tsukasa, Kikuchi, Maiko, Otomo, Haruka, Ihara, Keisuke, Kato, Hiroyuki
Format: Article
Language:English
Subjects:
Upper Gastrointestinal
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c408t-23e6a5519f387c723ac9c8137151e534327482663a958e7a2ce302dfb4df6fb43
cites cdi_FETCH-LOGICAL-c408t-23e6a5519f387c723ac9c8137151e534327482663a958e7a2ce302dfb4df6fb43
container_end_page 1158
container_issue 6
container_start_page 1153
container_title International surgery
container_volume 100
creator Satomura, Hitoshi
Nakajima, Masanobu
Sasaki, Kinro
Yamaguchi, Satoru
Domeki, Yasushi
Takahashi, Masakazu
Muroi, Hiroto
Kubo, Tsukasa
Kikuchi, Maiko
Otomo, Haruka
Ihara, Keisuke
Kato, Hiroyuki
description A dose-escalation study of docetaxel (DOC), cisplatin (CDDP), and 5-fluorouracil (5-FU; DCF combination regimen) was performed to determine the maximum-tolerated dose (MTD), recommended dose (RD) and dose-limiting toxicities (DLT) in advanced esophageal carcinoma. Eighteen patients with esophageal carcinoma were enrolled and received DCF combination therapy at different dose levels. DLTs included febrile neutropenia and oral mucositis. DLT occurred in 2 out of 6 patients at level 2 and 3. The study proceeded to level 4, according to the protocol. The level 4 dose was defined as the MTD and the level 3 dose was defined as the RD. The RD for DCF combination chemotherapy for advanced esophageal carcinoma in the present study was 70 mg/m2 DOC plus 70 mg/m2 CDDP on day 1 plus 700 mg/m2 5-FU on days 1–5 at 4-week intervals. This regimen was tolerable and highly active. A phase II study has been started.
doi_str_mv 10.9738/INTSURG-D-14-00233.1
format article
fullrecord <record><control><sourceid>pubmedcentral_cross</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4587522</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>pubmedcentral_primary_oai_pubmedcentral_nih_gov_4587522</sourcerecordid><originalsourceid>FETCH-LOGICAL-c408t-23e6a5519f387c723ac9c8137151e534327482663a958e7a2ce302dfb4df6fb43</originalsourceid><addsrcrecordid>eNpVkd1q3DAUhEVJaDZp36AXeoAo0a8t3wSCd5MuhCTkh16Ks7Icq9iSkbyh-xh94zrZUMjNGZiPGQ4MQj8YPatKoc_Xt0-Pzw_XZEmYJJRyIc7YF7TgilPCpSoO0GJ2KdG60EfoOOfflIpKqOorOuKFZFKLcoH-3neQHV7jZcyOrLKFHiYfA36cts0Ox3YG1k3wx_WnuPZ5fMPhFENosCJX_TamuE1gfY_rOGx82Kfrzg1x6lyCcYd9wPez7cKU8S8_dfiyeYVgXYNXOY4dvDiY05CsD3GAb-iwhT677x96gp6vVk_1T3Jzd72uL2-IlVRPhAtXgFKsaoUubckF2MpqJkqmmFNCCl5KzYtCQKW0K4FbJyhv2o1s2mK-4gRd7HvH7WZwjZ3fS9CbMfkB0s5E8OYzCb4zL_HVSKVLxflcIPcFNsWck2v_Zxk1bxOZj4nM0jBp3icyTPwDRXeG3A</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Phase I Dose-Escalation Study of Docetaxel, Cisplatin, and 5-Fluorouracil Combination Chemotherapy in Patients With Advanced Esophageal Carcinoma</title><source>PubMed Central</source><creator>Satomura, Hitoshi ; Nakajima, Masanobu ; Sasaki, Kinro ; Yamaguchi, Satoru ; Domeki, Yasushi ; Takahashi, Masakazu ; Muroi, Hiroto ; Kubo, Tsukasa ; Kikuchi, Maiko ; Otomo, Haruka ; Ihara, Keisuke ; Kato, Hiroyuki</creator><creatorcontrib>Satomura, Hitoshi ; Nakajima, Masanobu ; Sasaki, Kinro ; Yamaguchi, Satoru ; Domeki, Yasushi ; Takahashi, Masakazu ; Muroi, Hiroto ; Kubo, Tsukasa ; Kikuchi, Maiko ; Otomo, Haruka ; Ihara, Keisuke ; Kato, Hiroyuki</creatorcontrib><description>A dose-escalation study of docetaxel (DOC), cisplatin (CDDP), and 5-fluorouracil (5-FU; DCF combination regimen) was performed to determine the maximum-tolerated dose (MTD), recommended dose (RD) and dose-limiting toxicities (DLT) in advanced esophageal carcinoma. Eighteen patients with esophageal carcinoma were enrolled and received DCF combination therapy at different dose levels. DLTs included febrile neutropenia and oral mucositis. DLT occurred in 2 out of 6 patients at level 2 and 3. The study proceeded to level 4, according to the protocol. The level 4 dose was defined as the MTD and the level 3 dose was defined as the RD. The RD for DCF combination chemotherapy for advanced esophageal carcinoma in the present study was 70 mg/m2 DOC plus 70 mg/m2 CDDP on day 1 plus 700 mg/m2 5-FU on days 1–5 at 4-week intervals. This regimen was tolerable and highly active. A phase II study has been started.</description><identifier>ISSN: 0020-8868</identifier><identifier>EISSN: 2520-2456</identifier><identifier>DOI: 10.9738/INTSURG-D-14-00233.1</identifier><identifier>PMID: 26414837</identifier><language>eng</language><publisher>The International College of Surgeons, World Federation of General Surgeons and Surgical Specialists, Inc</publisher><subject>Upper Gastrointestinal</subject><ispartof>International surgery, 2015-06, Vol.100 (6), p.1153-1158</ispartof><rights>Copyright 2015 by the International College of Surgeons 2015</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c408t-23e6a5519f387c723ac9c8137151e534327482663a958e7a2ce302dfb4df6fb43</citedby><cites>FETCH-LOGICAL-c408t-23e6a5519f387c723ac9c8137151e534327482663a958e7a2ce302dfb4df6fb43</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4587522/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4587522/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids></links><search><creatorcontrib>Satomura, Hitoshi</creatorcontrib><creatorcontrib>Nakajima, Masanobu</creatorcontrib><creatorcontrib>Sasaki, Kinro</creatorcontrib><creatorcontrib>Yamaguchi, Satoru</creatorcontrib><creatorcontrib>Domeki, Yasushi</creatorcontrib><creatorcontrib>Takahashi, Masakazu</creatorcontrib><creatorcontrib>Muroi, Hiroto</creatorcontrib><creatorcontrib>Kubo, Tsukasa</creatorcontrib><creatorcontrib>Kikuchi, Maiko</creatorcontrib><creatorcontrib>Otomo, Haruka</creatorcontrib><creatorcontrib>Ihara, Keisuke</creatorcontrib><creatorcontrib>Kato, Hiroyuki</creatorcontrib><title>Phase I Dose-Escalation Study of Docetaxel, Cisplatin, and 5-Fluorouracil Combination Chemotherapy in Patients With Advanced Esophageal Carcinoma</title><title>International surgery</title><description>A dose-escalation study of docetaxel (DOC), cisplatin (CDDP), and 5-fluorouracil (5-FU; DCF combination regimen) was performed to determine the maximum-tolerated dose (MTD), recommended dose (RD) and dose-limiting toxicities (DLT) in advanced esophageal carcinoma. Eighteen patients with esophageal carcinoma were enrolled and received DCF combination therapy at different dose levels. DLTs included febrile neutropenia and oral mucositis. DLT occurred in 2 out of 6 patients at level 2 and 3. The study proceeded to level 4, according to the protocol. The level 4 dose was defined as the MTD and the level 3 dose was defined as the RD. The RD for DCF combination chemotherapy for advanced esophageal carcinoma in the present study was 70 mg/m2 DOC plus 70 mg/m2 CDDP on day 1 plus 700 mg/m2 5-FU on days 1–5 at 4-week intervals. This regimen was tolerable and highly active. A phase II study has been started.</description><subject>Upper Gastrointestinal</subject><issn>0020-8868</issn><issn>2520-2456</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><recordid>eNpVkd1q3DAUhEVJaDZp36AXeoAo0a8t3wSCd5MuhCTkh16Ks7Icq9iSkbyh-xh94zrZUMjNGZiPGQ4MQj8YPatKoc_Xt0-Pzw_XZEmYJJRyIc7YF7TgilPCpSoO0GJ2KdG60EfoOOfflIpKqOorOuKFZFKLcoH-3neQHV7jZcyOrLKFHiYfA36cts0Ox3YG1k3wx_WnuPZ5fMPhFENosCJX_TamuE1gfY_rOGx82Kfrzg1x6lyCcYd9wPez7cKU8S8_dfiyeYVgXYNXOY4dvDiY05CsD3GAb-iwhT677x96gp6vVk_1T3Jzd72uL2-IlVRPhAtXgFKsaoUubckF2MpqJkqmmFNCCl5KzYtCQKW0K4FbJyhv2o1s2mK-4gRd7HvH7WZwjZ3fS9CbMfkB0s5E8OYzCb4zL_HVSKVLxflcIPcFNsWck2v_Zxk1bxOZj4nM0jBp3icyTPwDRXeG3A</recordid><startdate>20150601</startdate><enddate>20150601</enddate><creator>Satomura, Hitoshi</creator><creator>Nakajima, Masanobu</creator><creator>Sasaki, Kinro</creator><creator>Yamaguchi, Satoru</creator><creator>Domeki, Yasushi</creator><creator>Takahashi, Masakazu</creator><creator>Muroi, Hiroto</creator><creator>Kubo, Tsukasa</creator><creator>Kikuchi, Maiko</creator><creator>Otomo, Haruka</creator><creator>Ihara, Keisuke</creator><creator>Kato, Hiroyuki</creator><general>The International College of Surgeons, World Federation of General Surgeons and Surgical Specialists, Inc</general><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope></search><sort><creationdate>20150601</creationdate><title>Phase I Dose-Escalation Study of Docetaxel, Cisplatin, and 5-Fluorouracil Combination Chemotherapy in Patients With Advanced Esophageal Carcinoma</title><author>Satomura, Hitoshi ; Nakajima, Masanobu ; Sasaki, Kinro ; Yamaguchi, Satoru ; Domeki, Yasushi ; Takahashi, Masakazu ; Muroi, Hiroto ; Kubo, Tsukasa ; Kikuchi, Maiko ; Otomo, Haruka ; Ihara, Keisuke ; Kato, Hiroyuki</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c408t-23e6a5519f387c723ac9c8137151e534327482663a958e7a2ce302dfb4df6fb43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Upper Gastrointestinal</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Satomura, Hitoshi</creatorcontrib><creatorcontrib>Nakajima, Masanobu</creatorcontrib><creatorcontrib>Sasaki, Kinro</creatorcontrib><creatorcontrib>Yamaguchi, Satoru</creatorcontrib><creatorcontrib>Domeki, Yasushi</creatorcontrib><creatorcontrib>Takahashi, Masakazu</creatorcontrib><creatorcontrib>Muroi, Hiroto</creatorcontrib><creatorcontrib>Kubo, Tsukasa</creatorcontrib><creatorcontrib>Kikuchi, Maiko</creatorcontrib><creatorcontrib>Otomo, Haruka</creatorcontrib><creatorcontrib>Ihara, Keisuke</creatorcontrib><creatorcontrib>Kato, Hiroyuki</creatorcontrib><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>International surgery</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Satomura, Hitoshi</au><au>Nakajima, Masanobu</au><au>Sasaki, Kinro</au><au>Yamaguchi, Satoru</au><au>Domeki, Yasushi</au><au>Takahashi, Masakazu</au><au>Muroi, Hiroto</au><au>Kubo, Tsukasa</au><au>Kikuchi, Maiko</au><au>Otomo, Haruka</au><au>Ihara, Keisuke</au><au>Kato, Hiroyuki</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Phase I Dose-Escalation Study of Docetaxel, Cisplatin, and 5-Fluorouracil Combination Chemotherapy in Patients With Advanced Esophageal Carcinoma</atitle><jtitle>International surgery</jtitle><date>2015-06-01</date><risdate>2015</risdate><volume>100</volume><issue>6</issue><spage>1153</spage><epage>1158</epage><pages>1153-1158</pages><issn>0020-8868</issn><eissn>2520-2456</eissn><abstract>A dose-escalation study of docetaxel (DOC), cisplatin (CDDP), and 5-fluorouracil (5-FU; DCF combination regimen) was performed to determine the maximum-tolerated dose (MTD), recommended dose (RD) and dose-limiting toxicities (DLT) in advanced esophageal carcinoma. Eighteen patients with esophageal carcinoma were enrolled and received DCF combination therapy at different dose levels. DLTs included febrile neutropenia and oral mucositis. DLT occurred in 2 out of 6 patients at level 2 and 3. The study proceeded to level 4, according to the protocol. The level 4 dose was defined as the MTD and the level 3 dose was defined as the RD. The RD for DCF combination chemotherapy for advanced esophageal carcinoma in the present study was 70 mg/m2 DOC plus 70 mg/m2 CDDP on day 1 plus 700 mg/m2 5-FU on days 1–5 at 4-week intervals. This regimen was tolerable and highly active. A phase II study has been started.</abstract><pub>The International College of Surgeons, World Federation of General Surgeons and Surgical Specialists, Inc</pub><pmid>26414837</pmid><doi>10.9738/INTSURG-D-14-00233.1</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0020-8868
ispartof International surgery, 2015-06, Vol.100 (6), p.1153-1158
issn 0020-8868
2520-2456
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4587522
source PubMed Central
subjects Upper Gastrointestinal
title Phase I Dose-Escalation Study of Docetaxel, Cisplatin, and 5-Fluorouracil Combination Chemotherapy in Patients With Advanced Esophageal Carcinoma
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T16%3A18%3A23IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmedcentral_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Phase%20I%20Dose-Escalation%20Study%20of%20Docetaxel,%20Cisplatin,%20and%205-Fluorouracil%20Combination%20Chemotherapy%20in%20Patients%20With%20Advanced%20Esophageal%20Carcinoma&rft.jtitle=International%20surgery&rft.au=Satomura,%20Hitoshi&rft.date=2015-06-01&rft.volume=100&rft.issue=6&rft.spage=1153&rft.epage=1158&rft.pages=1153-1158&rft.issn=0020-8868&rft.eissn=2520-2456&rft_id=info:doi/10.9738/INTSURG-D-14-00233.1&rft_dat=%3Cpubmedcentral_cross%3Epubmedcentral_primary_oai_pubmedcentral_nih_gov_4587522%3C/pubmedcentral_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c408t-23e6a5519f387c723ac9c8137151e534327482663a958e7a2ce302dfb4df6fb43%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/26414837&rfr_iscdi=true